GLP-1 drugs work for weight loss, study finds

Ozempic 3.0? This drug causes the greatest weight loss — by far
Ozempic 3.0? Retatrutide — an experimental drug nicknamed “triple G” — could be your best shot at a slimmer waistline when it becomes available to the public, a Monday study found. Obese adults who took the weekly injection lost up to 22% of their starting weight after 11 months — compared to just 14% over 15 months for semaglutide,
Some GLP-1s Achieve More Weight Loss Than Others: Study
By comparison, the FDA-approved drug liraglutide only resulted in just under 6% weight loss after 26 weeks, the researchers found. Common adverse side effects from the drugs included nausea, vomiting, diarrhea and constipation, researchers noted. However, side effects so bad people had to stop taking the drugs were rare.
As demand for weight-loss drugs rises, states grapple with Medicaid coverage
Over her three-decade career, weight management physician Dr. Sarah Ro has seen hundreds of patients. Many of them are on Medicaid and have become yo-yo dieters who, despite their best efforts at changing their eating habits and lifestyles,
Ozempic: Beyond Diabetes, A Breakthrough for Weight Loss?
None
Health Matters: GLP-1 drugs work for weight loss, study finds
McGill University researchers say their study has found GLP-1 drugs are safe and effective for treating obesity and overweight adults without diabetes. The authors say the findings support using the medication to treat those who are overweight and obese among otherwise healthy patients.
FDA issues draft guidance on developing weight loss drugs
The U.S. FDA has released a new draft guidance for drugmakers to aid them in developing new treatments for obesity. The new document replaces an earlier draft guidance issued in February 2007. The new guidance stated that its focus is on the design of clinical trials and endpoints to demonstrate sustained weight loss,
Should Medicaid Pay for Ozempic and Other Weight-Loss Drugs?
With 13 states offering coverage, it’s already a $3.9 billion cost. Some state officials say reducing obesity will save programs money in the long run.
Zepbound Weight Loss Medication Approved by FDA to Treat Sleep Apnea
The FDA suggests that prescribed users also reduce their calorie intake and increase their exercise The weight loss drug ...
Yahoo20d
FDA approves weight-loss drug Zepbound for obstructive sleep apnea
which was approved for weight loss for those with obesity, or who are overweight and have a weight-related health condition, in November 2023. Although the new FDA green light doesn’t expand ...
USA Today20d
The popular weight-loss drug Zepbound can now be used to treat sleep apnea
The Food and Drug Administration on Friday approved ... the FDA's director of the division of pulmonology, allergy and critical care. The FDA said the popular weight-loss drug should be ...
New York Post15d
FDA approves first medication for obstructive sleep apnea — which also promotes weight loss
The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA). On Dec. 20 ... “Zepbound promotes weight loss and has been shown to reduce ...
Yahoo19d
FDA approves weight-loss drug Zepbound to treat sleep apnea
The Food and Drug Administration has approved Zepbound, a GLP-1 weight-loss drug from Eli Lilly & Co ... apnea," said Dr. Sally Seymour of the FDA's Center for Drug Evaluation and Research.
Seattle Times20d
FDA approves weight-loss drug to treat obstructive sleep apnea
Advertising Even before the FDA approval, some doctors have been prescribing weight-loss drugs to people with sleep apnea. The FDA’s decision may place added pressure on insurance companies ...
6 Best Weight Loss Treatments: Ranking Top Weight Loss Solutions of 2025
Hims has become a leader in the weight loss treatment industry by offering access to men’s health solutions that are both ...
Becker's Hospital Review1d
GLP-1s cut surgery complication risk in some patients: Study
Glucagon-like peptide-1 receptor agonist drugs may reduce the risk of surgical complications in diabetic patients, according to a large new study. The study showed diabetic patients taking GLP-1 drugs ...